^
Association details:
Biomarker:MET overexpression
Cancer:Colorectal Cancer
Drug Class:EGFR inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies

Excerpt:
Our study has shown that higher T/NT ratios of ERBB2, MET and VEGFA mRNA were associated with worse OS in mCRC patients treated with anti-EGFR antibodies, with higher EREG and AREG were associated with better prognosis in the same setting.
DOI:
10.1038/bjc.2016.74